LSJ_FY25 Oseltamivir Phosphate_Redacted Version.pdf

This is a Limited Source Justification (LSJ) award notice for a firm-fixed-price delivery order awarded to Genentech USA, Inc. for the supply of oseltamivir phosphate (Tamiflu) with at least a 10-year shelf life. The Department of Health and Human Services' Administration for Strategic Preparedness and Response awarded contract 75A50325F80003 for $396,999,400 on January 31, 2025, with a 24-month period of performance.

The award specifically covers the replacement of expiring Tamiflu 30mg and 75mg capsules for the Strategic National Stockpile (SNS) with new capsules having an extended shelf life of at least 10 years. Genentech USA, Inc., located in South San Francisco, CA, was selected as the sole source provider due to their unique ability to supply the specialized product. The antiviral medication is used to treat acute Influenza A and B, working by inhibiting viral replication enzymes to reduce symptom severity and duration. The procurement falls under NAICS code 325412 for Pharmaceutical and Preparation Manufacturing.